Cholera Vaccines Market Regional Analysis

Cholera Vaccines Market size was valued at USD 79.07 Million in 2023 and is poised to grow from USD 84.84 Million in 2024 to USD 149.07 Million by 2032, growing at a CAGR of 7.30% during the forecast period (2025-2032).

The report provides a detailed analysis of the following key players in the global cholera vaccines market, including their competitive landscape, capacity, and most recent developments such as mergers, acquisitions, and investments, capacity expansions, and plant turnarounds. The presence of 'Sanofi S.A.', 'GlaxoSmithKline plc', 'PaxVax Inc. (now part of Emergent BioSolutions)', 'Bharat Biotech', 'Medtronics', 'EuBiologics Co. Ltd.', 'Shantha Biotechnics Private Limited (part of Sanofi Pasteur)', 'Bio Farma (Indonesia Vaccine Institute)', 'Eubiologics Co. Ltd.', 'Merck & Co., Inc.', 'Cipla Limited', 'Astellas Pharma Inc.', 'Takeda Pharmaceutical Company Limited', 'Panacea Biotec Ltd.', 'Serum Institute of India Pvt. Ltd.', 'Beijing Minhai Biotechnology Co. Ltd.', 'Biken Corporation', 'OCV Consortium (The Bill and Melinda Gates Foundation, WHO, and others)', 'PaxVax Bermuda Ltd.', 'GSK Biologicals SA.'

The development of creative methods to new cholera vaccines, increased awareness of cholera preventative care, and adoption of unhealthy lifestyle habits including poor sanitation and consumption of tainted food are the factors anticipated to propel the growth of the cholera vaccines market. Additionally, a greater focus on immunisation campaigns by the government has fueled the market expansion for cholera vaccines. The global cholera vaccines market, however, may be hindered by the FDA's stricter criteria and longer approval process for new drugs.

The global market is primarily driven by the increasing prevalence of cholera among the general population. This is due to poor sanitation and hygiene conditions in rural and geographically remote areas. Furthermore, rising public awareness of the availability of cholera vaccines has boosted product demand.

The market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa (MEA). According to regional analysis, Asia-Pacific has the largest market share. This is due to increased access to effective preventive measures, rise in public awareness of the disease, and the disease's high incidence rate. Europe is also expected to grow steadily during the forecast period, owing to the region's well-established healthcare infrastructure. North America, on the other hand, is expected to grow at a faster rate during the forecast period, owing to rising consumption of contaminated food, a lack of appropriate hygiene, and an increasing number of migrants. At the same time, increased R&D activities, rising public awareness of vaccination, and rising government initiatives to conduct immunisation programmes would all contribute to the growth of the cholera vaccine market in this region.